KDIGO – aHUS controversies and consensus
Six years ago, aHUS featured, along with another renal disease MPGN/C3G, in a controversies conference held by KDIGO (Kidney Disease Improving…
aHUS Trial Watch 14
A trial has been designed by Alexion to examine the efficacy of Ravulizumab to treat those with a Thrombotic Microngiopathy ,…
Good complement goes aHUS bad
OK, so HUS is caused by e.coli toxins and aHUS results from Complement dysregulation. Both are thrombotic microangiopathies. HUS is…
aHUS Diagnosis & Treatment – KDIGO Controversy Conference
The KDIGO Controversies Conference on Complement-Mediated Kidney Disease was held November 19-21 2015 in Barcelona Spain. KDIGO’s mission is to…